Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3885-3892

  Horiguchi, Yutaka ^a   Nukaya, Ikuei ^b   Okazawa, Kazuhide ^b   Kawashima, Ichiro ^b   Fikes, John ^d   Sette, Allesandro ^d   Tachibana, Masaaki ^c   Takesako, Kazutoh ^b   Murai, Masaru ^a  

^a KEIO UNIVERSITY   (Japan)

^b TAKARA BIO INC   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d Epimmune   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINYLTYROSYLALANYLARGINYLTHREONYLGLUTAMYLASPARTYLPHENYLALANYLPHENYLAL ANINE; LEUCYLTYROSYLASPARAGINYLPHENYLALANYLTHREONYLGLUTAMINYLISOLEUCYLPROLYLHISTID YLLEUCINE; LYSYLTYROSYLALANYLGLYCYLGLUTAMYLSERYLPHENYLALANYLPROLYLGLYCYLISOLEUCINE; PHENYLALANYLTYROSYLASPARTYLPROLYLMETHIONYLPHENYLALANYLLYSYLTYROSYLHISTIDYLL EUCINE; THREONYLTYROSYLSERYLVALYLSERYLPHENYLALANYLASPARTYLSERYLLEUCYLPHENYLALANINE; AMINO ACID; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; GLYCYLTYROSYLTYROSYLASPARTYLALANYLGLUTAMINYLLYSYLLEUCYLLEUCINE; HLA A24 ANTIGEN; HORMONE; LEUCYLTYROSYLSERYLASPARTYLPROLYLALANYLASPARTYLTYROSYLPHENYLALANINE; LEUKOCYTE ANTIGEN; LYSYLTYROSYLALANYLASPARTYLLYSYLISOLEUCYLTYROSYLSERYLISOLEUCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; THREONYLTYROSYLSERYLVALYLSERYLPHENYLALANYLSERYLLEUCINE; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOBLAST; BINDING ASSAY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; LYMPHOID CELL LINE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MOTIF; SCREENING; TARGET CELL; TUMOR CELL LINE;

EID: 0036897522     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Horoszewicz, J. S., Kawinski, E., and Murphy, G. P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res., 7: 927-935, 1987.
2. Israeli, R. S., Powell. C. T., Fair, W. R., and Heston, W. D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res., 53: 227-230, 1993.
3. Israeli, R. S., Powell, C. T., Corr, J. G., Fair, W. R., and Heston, W. D. Expression of the prostate-specific membrane antigen. Cancer Res., 54: 1807-1811, 1994,
4. 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate, 18: 229-241, 1991.
5. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J. Urol., 152: 1490-1495, 1994.
6. 90-CYT-356 monoclonal antibody. Clin. Cancer Res., 2: 1289-1297, 1996.
7. Gong, M. C., Chang, S. S., Sadelain, M., Bander, N. H., and Heston, W. D. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev., 18: 483-490, 1999.
8. Holmes, E. H. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin. Investig. Drugs, 10: 511-519, 2001.
9. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostatespecific membrane antigen. Prostate. 29: 371-380, 1996.
10. Salgaller, M. L., Thurnher, M., Bartsch. G., Boynton, A. L., and Murphy, G. P. Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials. Cancer (Phila.), 86: 2674-2683, 1999.
11. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Jarisch, J., Bowes, V. A., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Salgaller, M. L., and Boynton, A. L. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate, 38: 73-78, 1999.
12. Tjoa, B. A., Simmons, S. J., Elgamal, A., Rogers, M., Ragde, H., Kenny, G. M., Troychak, M. J., Boynton, A. L., and Murphy, G. P. Follow-up evaluation of a Phase II prostate cancer vaccine trial. Prostate, 40: 125-129, 1999.
13. Date, Y., Kimura, A., Kato, H., and Sasazuki, T. DNA typing of the HLA-A gene: Population study and identification of four new alleles in Japanese. Tissue Antigens, 47: 93-101, 1996.
14. Long, E. O., Rosen-Bronson, S., Karp, D. R., Malnati, M., Sekaly, R. P., and Jaraquemada, D. Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cells. Hum. Immunol., 31: 229-235, 1991.
15. Zhu, Z. Y., Zhong, C. P., Xu, W. F., Lin, G. M., Ye, G. Q., Ji, Y. Y., Sun, B., and Yeh, M. PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response. Cell Res., 9: 271-280, 1999.
16. Kondo, A., Sidney, J., Southwood, S., del Guercio, M. F., Appella, E., Sakamoto, H., Celis, E., Grey, H. M., Chesnut, R. W., Kubo, R. T., and Sette, A. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J. Immunol., 155: 4307-4312, 1995.
17. Nukaya, I., Yasumoto, M., Iwasaki, T., Ideno, M., Sette, A., Celis, E., Takesako, K., and Kato, I. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int. J. Cancer, 80: 92-97, 1999.
18. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., and Riddell, S. R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med., 333: 1038-1044, 1995.
19. Kubo, R. T., Sette, A., Grey, H. M., Appella, E., Sakaguchi, K., Zhu, N. Z., Arnott, D., Sherman. N., Shabanowitz, J., and Michel, H. Definition of specific peptide motifs for four major HLA-A alleles. J. Immunol., 152: 3913-3924, 1994.
20. Sokoloff, M. H., Tso, C. L., Kaboo, R., Taneja, S., Pang, S., deKernion, J. B., and Belldegrun, A. S. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer (Phila.), 77: 1862-1872, 1996.
21. Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A., Navarro, V., Knudsen, B., and Bander, N. H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res., 57: 3629-3634, 1997.
22. Chang, S. S., O'Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D., and Gaudin, P. B. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res., 5: 2674-2681, 1999.
23. Wright, G. L., Jr., Grob, B. M., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., and Moriarty, R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 48: 326-334, 1996.
24. Kawakami, M., and Nakayama, J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res., 57: 2321-2324, 1997.
25. Bostwick, D. G., Pacelli, A., Blute, M., Roche, P., and Murphy, G. P. Prostate specific membrane antigen expression in prostatic intra-epithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer (Phila.), 82: 2256-2261, 1998.
26. Salgaller, M. L., Lodge, P. A., McLean, J. G., Tjoa, B. A., Loftus, D. J., Ragde, H., Kenny, G. M., Rogers, M., Boynton, A. L., and Murphy, G. P. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate, 35: 144-151, 1998.
27. Sudo, T., Kamikawaji, N., Kimura, A., Date, Y., Savoie, C. J., Nakashima, H., Furuichi, E., Kuhara, S., and Sasazuki, T. Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J Immunol, 155: 4749-4756, 1995.
28. Wei, C., Willis. R. A., Tilton, B. R., Looney, R. J., Lord, E. M., Barth, R. K., and Frelinger, J. G. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: I Proc. Natl. Acad. Sci. USA, 94: 6369-6374, 1997.
29. Terasawa, H., Tsang, K. Y., Gulley, J., Arlen, P., and Schlom, J. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin. Cancer Res., 8: 41-53, 2002.
30. Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe, B., Coulie, P., and Boon, T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med., 178: 489-495, 1993.
31. Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor, C. G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med., 179: 1005-1009, 1994.
32. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA. 91: 3515-3519, 1994.
33. Wang, R. F., Robbins, P. F., Kawakami, Y., Kang, X. Q., and Rosenberg, S. A. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med., 181: 799-804, 1995.
34. Tanaka, F., Fujie, T., Go, H., Baba, K., Mori, M., Takesako, K., and Akiyoshi, T. Efficient induction of antitumor cytotoxic T lymphocytes from a healthy donor using HLA-A2-restricted MAGE-3 peptide in vitro. Cancer Immunol. Immunother., 44: 21-26, 1997.
35. Fujie, T., Tanaka, F., Mori, M., Takesako, K., Sugimachi, K., and Akiyoshi, T. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro. Clin. Cancer Res., 3: 2425-2430, 1997.
36. Kawashima, I., Tsai, V., Southwood, S., Takesako, K., Celis, E., and Sette, A. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int. J. Cancer, 78: 518-524, 1998.
37. Tanaka, H., Tsunoda, T., Nukaya, I., Sette, A., Matsuda, K., Umano, Y., Yamaue, H., Takesako, K., and Tanimura, H. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: Possible immunotherapy for colorectal carcinomas. Br. J. Cancer, 84: 94-99, 2001.
38. Grey, H. M., Ruppert, J., Vitiello, A., Sidney, J., Kast, W. M., Kubo, R. T., and Sette, A. Class I MHC-peptide interactions: Structural requirements and functional implications. Cancer Surv., 22: 37-49, 1995.